TrueCAGR

Fortis Healthcare Ltd

NSE: FORTISBSE: 532843ISIN INE061F01013Face value ₹10consolidated
₹825
+2.00% · 2026-11-20 · 52-wk ₹720–₹990
Source: BSE filings · Financials to FY2026 · 8 years of history · Data last updated: results filed 5 Nov 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
StrengthTalking point

Profit outpacing revenue

Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.

Net profit growth+31.5%Revenue growth+17.3%

Importance 63 / 95 · growth

StrengthTalking point

Margins at a multi-year high

EBITDA margin of 23.4% is the widest in 7 years (prior range 7.1% to 21.3%).

Importance 53 / 95 · profitability

Strength

Earnings consistently backed by cash

Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.51×).

Importance 50 / 95 · cash quality

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.

Market cap
₹62,284 cr
FY2026 revenue
₹9,128 cr
FY2026 net profit
₹1,064 cr
Net worth
₹10,169 cr
Total debt
₹2,873 cr
EPS (basic)
₹13.80
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 3 hospital.

Section 04 · Business performance

Is the business growing?

Revenue grew 10.7% a year over 7 years, from ₹4,469 cr in FY2019 to ₹9,128 cr in FY2026. Net profit moved from a loss of ₹224 cr in FY2019 to a profit of ₹1,064 cr in FY2026.

Revenue & net profit — FY19 to FY26₹ crore · consolidated
₹'000 cr035810012REVENUENET PROFIT4k-224FY195k91FY204k-56FY216k790FY226k633FY237k645FY248k809FY259k1,064FY26
RevenueNet profit
Strength

Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.

Rule PROFIT_FASTER_THAN_REVENUE

Revenue growth per year
+10.7%over 7 years (FY19–FY26)
Revenue growth
+17.3%vs last year
Net profit growth
+31.5%vs last year
Change in net profit since FY19
+576%

Net profit grew 31.5% year on year (FY2025 → FY2026).

Revenue grew 17.3% year on year (FY2025 → FY2026).

Revenue has compounded at 10.7% a year over 7 years (₹4,469 → ₹9,128) — steady rather than rapid.

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,735 cr (up 17.3% on the same quarter last year) and net profit ₹320 cr (down 2.5%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Strength

Q2 FY27 revenue was ₹2,735 cr, up 17.3% from ₹2,331 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

Strength

Q2 FY27 revenue of ₹2,735 cr is the highest of the 17 quarters on record for this company.

Rule QTR_REVENUE_AT_RECORD

Concern

Q2 FY27 EBITDA margin was 23.0%, down 1.80 percentage points from 24.8% a year earlier.

Rule QTR_MARGIN_CHANGED_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01223000REVENUENET PROFIT2k254Q3 '252k188Q4 '252k267Q1 '262k329Q2 '262k197Q3 '262k271Q4 '263k273Q1 '273k320Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY251,928+14.8%254+89.5%13.2%
Q4 FY252,007+12.4%188−7.4%9.4%
Q1 FY262,167+16.6%267+53.3%12.3%
Q2 FY262,331+17.3%329+70.3%14.1%
Q3 FY262,265+17.5%197−22.4%8.7%
Q4 FY262,365+17.8%271+44.2%11.5%
Q1 FY272,545+17.5%273+2.3%10.7%
Q2 FY272,735+17.3%320−2.5%11.7%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹9,910 crTTM
EBITDA
₹2,232 crTTM
EBIT
₹1,740 crTTM
PBT
₹1,365 crTTM
Net profit
₹1,062 crTTM

C. Corporate actions

24 Jul 2026DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
25 Jul 2025DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
24 Jul 2024DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
20 Jul 2023DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
18 Aug 2009Rights issueRight Issue of Equity Shares with Warrants
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 23.4% in FY2026, against 7.1% in FY2019. ROE was 11.0% and ROCE 13.7% in FY2026.

Margins — FY19 to FY26% of revenue · consolidated
-5%0%5%10%15%20%25%23.4%11.6%FY19FY20FY21FY22FY23FY24FY25FY26
EBITDA marginNet margin
Strength

EBITDA margin of 23.4% is the widest in 7 years (prior range 7.1% to 21.3%).

Rule MARGIN_AT_MULTI_YEAR_HIGH

EBITDA margin now
23.4%
8-year range
7.1–23.4%
ROE FY2026
11.0%
ROCE FY2026
13.7%

ROE improved from 9.1% to 11.0% year on year.

EBITDA margin improved from 21.3% to 23.4% of revenue.

Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.28x in FY2026, against 0.27x in FY2019; interest coverage 5.36x. Operating cash flow was 1.51x net profit.

Net worth — FY19 to FY26₹ crore · consolidated
₹'000 cr0713207kFY197kFY207kFY217kFY228kFY239kFY249kFY2510kFY26
Net worth (shareholders' funds)
Strength

Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.51×).

Rule CFO_CONSISTENTLY_EXCEEDS_PAT

Operating cash flow vs net profit₹ crore · FY21–FY26
0k1k1k2k486-56FY21865790FY22822633FY231k645FY241k809FY252k1kFY26
Operating cash flowNet profit
Total debt
₹2,873 cr
Operating cash flow ÷ net profit
1.51×FY2026
Free cash flow
₹673 cr
Current ratio
0.86×

Free cash flow has been positive in 6 of the last 6 years.

Section 08 · Relative position

How does it compare with peers?

Within its 3-company Hospital peer group, it ranks 3 of 3 on return on equity and 2 of 3 on EBITDA margin. Its P/E of 58.7 compares with a peer median of 58.7.

Ranked against 3 hospital (FY2026, consolidated).

Revenue growth

FORTIS · 2nd of 3 · set median 17.3%

MAXHEALTH19.1%FORTIS17.3%APOLLOHOSP15.8%

EBITDA margin

FORTIS · 2nd of 3 · set median 23.4%

MAXHEALTH28.7%FORTIS23.4%APOLLOHOSP15.7%

Return on equity

FORTIS · 3rd of 3 · set median 14.3%

APOLLOHOSP21.5%MAXHEALTH14.3%FORTIS11.0%

P/E ratio

FORTIS · 2nd of 3 · set median 58.7×

APOLLOHOSP56.5×FORTIS58.7×MAXHEALTH76.1×
Context

Trades at 6.13× book — 37% below the hospital median of 9.78×.

Rule PB_BELOW_PEERS

P / E
58.7×TTM to Sept 26
P / B
6.1×latest book
P / S
6.3×TTM sales
Earnings yield
1.7%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 58.5× · P/S 6.8× · ROE 11.0%.

Section 09 · The stock

How has the stock performed?

The share price is down 11.8% over 1 year, up 122% over 3 years (30.4% a year) and up 191% over 5 years (23.9% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 16.7% below its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k₹8252020202120222023202420252026
Context

Over 6 years profit compounded at 50.5% a year while the stock returned 23.9% a year — but FY2020 profit (₹91) was well below the through-cycle level (~₹645), so this rate is inflated by the recovery from a low base.

Rule STOCK_LAGGED_EARNINGS · recovery

Business vs stock — 5-year compound annual rate
Net profit50.5%/yrShare price23.9%/yr
1-year return
−11.8%
3-year return
+121.5%
5-year return
+191.4%
From 52-wk high
−16.7%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹800
vs 200-day avg
Below₹890
RSI (14)
60.6neutral
MACD histogram
8.4
From 52-wk high
−16.7%
From 52-wk low
+14.6%
30-day volatility
34.7%ann.
6-month return
−15.3%
RSI (14) · 0–10060.6 — neutral
0305070100OVERSOLDOVERBOUGHT60.6
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

Nothing is flagged for review for this company.

  • Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
  • The price-adjusted series does not correct for a rights issue (ex-date 2009-08-18) — BSE's corporate-actions feed does not carry the subscription price or ratio a rights adjustment needs, unlike splits and bonuses, which are corrected. Returns spanning that date may be modestly overstated or understated.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY19FY20FY21FY22FY23FY24FY25FY26
Revenue4,4694,6324,0305,7186,2986,8937,7839,128
Total income4,5624,6854,0775,7456,3596,9317,8509,179
EBITDA3186624511,0961,1631,3061,6552,136
Profit before tax−475227−49647928489961,350
Net profit−22491−567906336458091,064
EPS (₹)−3.70.8−0.77.37.87.910.313.8
Net worth7,1127,2066,7187,0088,1008,5569,16910,169
Total debt1,9051,5291,4071,2559268582,4752,873
Operating cash flow——4868658221,1001,4241,602
Free cash flow——267750397172617673
Key ratios — consolidated
RatioFY19FY20FY21FY22FY23FY24FY25FY26
Growth
Revenue growth YoY—3.6-13.041.910.19.512.917.3
Profit growth YoY————-19.91.925.431.5
Profitability
EBITDA margin %7.114.311.219.218.518.921.323.4
Net margin %-4.92.0-1.413.810.09.310.311.6
Return on equity %-3.11.3-0.811.58.47.79.111.0
Return on capital %0.94.21.99.79.810.412.113.7
Leverage & cash
Debt to equity0.270.210.210.180.110.100.270.28
Cash flow ÷ profit———1.101.301.701.761.51
Current ratio0.620.621.251.321.390.691.350.86
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.